Cargando…

Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis

IMPORTANCE: Identifying biomarkers of treatment response is an urgent need in the treatment of tuberculosis (TB). Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) are potential diagnostic biomarkers in pulmonary TB (PTB). OBJECTIVE: To assess whether baseli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Nathella P., Moideen, Kadar, Nancy, Arul, Viswanathan, Vijay, Thiruvengadam, Kannan, Sivakumar, Shanmugam, Hissar, Syed, Nair, Dina, Banurekha, Vaithilingam V., Kornfeld, Hardy, Babu, Subash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709089/ https://www.ncbi.nlm.nih.gov/pubmed/33258908 http://dx.doi.org/10.1001/jamanetworkopen.2020.27754

Ejemplares similares

Effect of anti-tuberculosis treatment on the systemic levels of tissue inhibitors of metalloproteinases in tuberculosis – Diabetes co-morbidity
por: Kumar, Nathella Pavan, et al.
Publicado: (2021)

Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Are Potential Biomarkers of Pulmonary and Extra-Pulmonary Tuberculosis
por: Kathamuthu, Gokul Raj, et al.
Publicado: (2020)

Acute Phase Proteins Are Baseline Predictors of Tuberculosis Treatment Failure
por: Kumar, Nathella Pavan, et al.
Publicado: (2021)

Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment
por: Kumar, Nathella P., et al.
Publicado: (2018)

Plasma Eicosanoid Levels in Tuberculosis and Tuberculosis-Diabetes Co-morbidity Are Associated With Lung Pathology and Bacterial Burden
por: Pavan Kumar, Nathella, et al.
Publicado: (2019)

Systemic RAGE ligands are upregulated in tuberculosis individuals with diabetes co-morbidity and modulated by anti-tuberculosis treatment and metformin therapy
por: Kumar, Nathella Pavan, et al.
Publicado: (2019)

Helminth Coinfection Is Associated With Enhanced Plasma Levels of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Tuberculous Lymphadenitis
por: Kathamuthu, Gokul Raj, et al.
Publicado: (2021)

Chitinase and indoleamine 2, 3-dioxygenase are prognostic biomarkers for unfavorable treatment outcomes in pulmonary tuberculosis
por: Kumar, Nathella Pavan, et al.
Publicado: (2023)

Plasma chemokines are biomarkers of disease severity, higher bacterial burden and delayed sputum culture conversion in pulmonary tuberculosis
por: Kumar, Nathella P., et al.
Publicado: (2019)

Heightened circulating levels of antimicrobial peptides in tuberculosis—Diabetes co-morbidity and reversal upon treatment
por: Kumar, Nathella Pavan, et al.
Publicado: (2017)

Role of matrix metalloproteinases in multi-system inflammatory syndrome and acute COVID-19 in children
por: Pavan Kumar, Nathella, et al.
Publicado: (2022)

Low body mass index is associated with diminished plasma cytokines and chemokines in both active and latent tuberculosis
por: Kumar, Nathella Pavan, et al.
Publicado: (2023)

IL-27 and TGFβ mediated expansion of Th1 and adaptive regulatory T cells expressing IL-10 correlates with bacterial burden and disease severity in pulmonary tuberculosis
por: Kumar, Nathella P, et al.
Publicado: (2015)

Coincident Pre-Diabetes Is Associated with Dysregulated Cytokine Responses in Pulmonary Tuberculosis
por: Kumar, Nathella Pavan, et al.
Publicado: (2014)

Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis
por: Kumar, Nathella Pavan, et al.
Publicado: (2016)

Diminished plasma levels of common γ-chain cytokines in pulmonary tuberculosis and reversal following treatment
por: Kumar, Nathella Pavan, et al.
Publicado: (2017)

Altered circulating levels of B cell growth factors and their modulation upon anti-tuberculosis treatment in pulmonary tuberculosis and tuberculous lymphadenitis
por: Kathamuthu, Gokul Raj, et al.
Publicado: (2018)

Altered Circulating Levels of Matrix Metalloproteinases and Inhibitors Associated with Elevated Type 2 Cytokines in Lymphatic Filarial Disease
por: Anuradha, Rajamanickam, et al.
Publicado: (2012)

Functional relationship between matrix metalloproteinase-11 and matrix metalloproteinase-14
por: Buache, Emilie, et al.
Publicado: (2014)

Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in the hair cycle
por: HOU, CHUN, et al.
Publicado: (2016)

Matrix metalloproteinases and epileptogenesis
por: Ikonomidou, Chrysanthy
Publicado: (2014)

Matrix Metalloproteinases and Glaucoma
por: Kim, Moo Hyun, et al.
Publicado: (2022)

Expansion of Pathogen-Specific Mono- and Multifunctional Th1 and Th17 Cells in Multi-Focal Tuberculous Lymphadenitis
por: Kumar, Nathella Pavan, et al.
Publicado: (2013)

Matrix Metalloproteinases in Health and Disease in the Times of COVID-19
por: Fernandez-Patron, Carlos, et al.
Publicado: (2022)

Matrix Metalloproteinases in Cerebral Ischemia
por: Kim, Hahn Young, et al.
Publicado: (2006)

Matrix metalloproteinases in arthritic disease
por: Murphy, Gillian, et al.
Publicado: (2002)

Matrix metalloproteinases in lung biology
por: Parks, William C, et al.
Publicado: (2001)

Matrix metalloproteinases in exercise and obesity
por: Jaoude, Jonathan, et al.
Publicado: (2016)

Matrix Metalloproteinases and Glaucoma Treatment
por: Weinreb, Robert N., et al.
Publicado: (2020)

Challenges in Matrix Metalloproteinases Inhibition
por: Laronha, Helena, et al.
Publicado: (2020)

Matrix Metalloproteinases in Health and Disease
por: Serra, Raffaele
Publicado: (2020)

Matrix metalloproteinases in keratinocyte carcinomas
por: Riihilä, Pilvi, et al.
Publicado: (2020)

Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissuenhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase
por: Collins, H M, et al.
Publicado: (2001)

Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
por: Tanaka, Komei, et al.
Publicado: (2013)

Plasma chemokines as immune biomarkers for diagnosis of pediatric tuberculosis
por: Kumar, Nathella Pavan, et al.
Publicado: (2021)

Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer
por: Tanioka, Y, et al.
Publicado: (2003)

Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
por: Guzel, Savas, et al.
Publicado: (2013)

Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients
por: Trentini, Alessandro, et al.
Publicado: (2016)

Matrix Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Aqueous Humor of Diabetic Macular Edema Patients
por: Kwon, Jin-woo, et al.
Publicado: (2016)

Matrix metalloproteinases in human gliomas: activation of matrix metalloproteinase-2 (MMP-2) may be correlated with membrane-type-1 matrix metalloproteinase (MT1-MMP) expression.
por: Hur, J. H., et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_7vr5jpdb2p2n69sjjids1p4fd3